Document:

EX-10.12

 Exhibit 10.12 

CONSULTING AGREEMENT 

THIS CONSULTING AGREEMENT (this “Agreement”), effective as of July 25, 2013 (“Effective Date”), is by and between
THOMAS J. VAN HAARLEM, M.D., having an address at 14 Blue Cliff Drive, Lebanon, NJ 08833 (hereinafter referred to as “Consultant”) and AERIE PHARMACEUTICALS, INC., a Delaware corporation having offices at 135 US Highway 206, Suite 9,
Bedminster, NJ 07921 (“Aerie” or the “Company”). 
 W I T N E S S E T H: 

WHEREAS, Aerie is a development stage company that is engaged in research and development of ophthalmic products (the
“Field”). 
 WHEREAS, Consultant has significant experience relating to the Company and its products; 

WHEREAS, Aerie desires to retain Consultant so that it may call upon Consultant’s knowledge and expertise; 

WHEREAS, Consultant is willing to render such services to Aerie on the terms and conditions hereinafter set forth in this Agreement;

 NOW, THEREFOR, in consideration of the mutual covenants and agreements hereinafter set forth, the parties hereby agree as
follows: 
 1. Term of Agreement. This Agreement shall be in effect from the Effective Date until June 30, 2014 (the
“Term”). 
 2. Services. Consultant shall report to the CEO of the Company and shall be available during the Term upon
reasonable request by Aerie, to consult with Aerie to offer advice and guidance. The Services may include limited travel. Any travel expenses will be reimbursed by the Aerie in accordance with Section 4 below. 

3. Compensation. 
 (a) In
consideration for the Services of Consultant, Aerie shall pay Consultant an amount equal to One Hundred Dollars ($100.00) per month. 
 (b)
Consultant is the holder of 139,833 shares of Series A-4 Preferred Stock and options to purchase 2,426,504 shares of common stock of the Company (the “Options”), of which 2,218,114 Options are currently vested and exercisable (the
“Vested Options”). Subject to the terms contained herein, as additional consideration for the Services the Company agrees: 
 (i)
to extend the exercise period of all Vested Options until June 30, 2014 (the “Expiration Date”); 

  
 1 

 (ii) that all unvested Options (“Unvested Options”) shall continue to vest in
accordance with the current vesting schedule associated with such Unvested Options, such that 208,390 Options shall vest on or before the Expiration Date; provided, however, that all Unvested Options shall remain unvested as of the Expiration Date
shall expire immediately. 
 (iii) Consultant shall be entitled to exercise any Options by means of a “cashless exercise” in
which the Consultant shall be entitled to receive a number of shares of common stock equal to the quotient obtained by dividing [(A-B) (X)] by (A), where: 

(A) = the fair market value of the common stock of the Company on the date of exercise as determined in good faith by the Board of Directors;

 (B) = the exercise price of the Option; and 

(X) = the number of shares of common stock that would be issuable upon exercise of the Option if such exercise were by means of a cash
exercise rather than a cashless exercise. 
 (iv) Notwithstanding anything herein to the contrary, all Options that have not been exercised
on or prior to the Expiration Date shall expire at the close of business on the Expiration Date. 
 4. Expenses. Aerie shall
reimburse Consultant for all normal, usual and necessary expenses incurred by Consultant in furtherance of the business and affairs of Aerie, including reasonable pre-approved travel and entertainment expenses, upon timely receipt by Aerie of
appropriate documentation of Consultant’s expenditures and otherwise in accordance with any expense reimbursement policy as may from time to time be adopted by Aerie. 

5. Confidentiality and Invention Assignment. 

(a) Consultant recognizes and acknowledges that in the course of his Services he is likely to receive confidential or proprietary information
owned by the Company, its affiliates or third parties with whom the Company or any such affiliates has an obligation of confidentiality. Accordingly, during and after the Term and for a period of 10 years thereafter, Consultant agrees to keep
confidential and not disclose or make accessible to any other person or use for any other purpose other than in connection with the fulfillment of his duties under this Agreement, any Confidential and Proprietary Information (as defined below) owned
by, or received by or on behalf of, the Company or any of its affiliates. “Confidential and Proprietary Information” shall include, but shall not be limited to, confidential or proprietary scientific or technical information, data,
formulas and related concepts, business plans (both current and under development), client lists, promotion and marketing programs, trade secrets, or any other confidential or proprietary business information relating to development programs, costs,
revenues, marketing, investments, sales activities, promotions, credit and financial data, manufacturing processes, financing methods, plans or the business and affairs of the Company or of any affiliate or client of the Company. Additionally,
information that, by its nature and content, would be readily recognized by a 

  
 2 

 
reasonable person to be proprietary to the Company shall also be deemed Confidential and Proprietary Information. Consultant expressly acknowledges the trade secret status of the Confidential and
Proprietary Information and that the Confidential and Proprietary Information constitutes a protectable business interest of the Company. Consultant agrees not to: 

(i) use any such Confidential and Proprietary Information for personal use or for others; and 

(ii) permanently remove any Company material or reproductions (including but not limited to writings, correspondence, notes, drafts, records,
invoices, technical and business policies, computer programs or disks) thereof from the Company’s offices at any time during his employment by the Company, except as required in the execution of Consultant’s duties to the Company,
provided; however, that Consultant shall not be prevented from using or disclosing any Confidential and Proprietary Information: 
 A. that
Consultant can demonstrate was known to his prior to the effective date of this Agreement; 
 B. that is now, or becomes in the future,
available to persons who are not legally required to treat such information as confidential unless such persons acquired the Confidential and Proprietary Information through acts or omissions of Consultant; or 

C. that Consultant is compelled to disclose pursuant to the order of a court or other governmental or legal body having jurisdiction over
such matter, provided that (1) Consultant shall give Company sufficient advance written notice of such required disclosure to permit it to seek a protective order or other similar order with respect to such Confidential Information, and
(2) thereafter Consultant shall disclose only the minimum Confidential Information required to be disclosed in order to comply, whether or not a protective order or other similar order is obtained by the Company. The Confidential Information
that is disclosed pursuant to this paragraph shall remain Confidential Information for all other purposes. 
 (b) Consultant agrees to
return immediately all Company material and reproductions (including but not limited, to writings, correspondence, notes, drafts, records, invoices, technical and business policies, computer programs or disks) thereof in his possession to the
Company upon request and in any event immediately upon termination of employment. 
 (c) Except with prior written authorization by the
Company, Consultant agrees not to disclose or publish any of the Confidential and Proprietary Information, or any confidential, scientific, technical or business information of any other party to whom the Company or any of its affiliates owes a
legal duty of confidence, at any time during or after his employment with the Company. 

  
 3 

 (d) Consultant agrees that all inventions, discoveries, improvements and patentable or
copyrightable works, relating to the Company’s business (“Inventions”) initiated, conceived or made by her, either alone or in conjunction with others, during the Term shall be the sole property of the Company to the maximum extent
permitted by applicable law and, to the extent permitted by law, shall be “works made for hire” as that term is defined in the United States Copyright Act (17 U.S.C.A., Section 101). The Company shall be the sole owner of all patents,
copyrights, trade secret rights, and other intellectual property or other rights in connection therewith. Consultant hereby assigns to the Company all right, title and interest he may have or acquire in all such Inventions; provided, however, that
the Board may in its sole discretion agree to waive the Company’s rights pursuant to this Section 5(d) with respect to any Invention that is not directly or indirectly related to the Company’s business. Consultant further agrees to
assist the Company in every proper way (but at the Company’s expense) to obtain and from time to time enforce patents, copyrights or other rights on such Inventions in any and all countries, and to that end Consultant will execute all documents
necessary: 
 (i) to apply for, obtain and vest in the name of the Company alone (unless the Company otherwise directs) letters patent,
copyrights or other analogous protection in any country throughout the world and when so obtained or vested to renew and restore the same; and 

(ii) to defend any opposition proceedings in respect of such applications and any opposition proceedings or petitions or applications for
revocation of such letters patent, copyright or other analogous protection. 
 (e) The provisions of this Section 5 shall survive any
termination of this Agreement. 
 6. Non-Solicitation; Non-Disparagement. 

(a) During the Term and for a period of 12 months thereafter, Consultant shall not, directly or indirectly, without the prior written consent
of the Company: 
 (i) solicit or induce any employee of the Company or any of its subsidiaries to leave the employ of the Company or such
subsidiaries; or 
 (ii) solicit the business of any agent, client or customer of the Company or any of its subsidiaries with respect to
products or services similar to and competitive with those provided or supplied by the Company or any of its subsidiaries. 
 (b) Consultant
agrees that both during the Term and at all times thereafter, not to make or encourage any other individual to make any public or private comments, orally or in written form (including, without limitation by e-mail or other electronic transmission),
about the Company or any of its officers, directors or managers, or take any action, directly or indirectly, that would “disparage” the Company or such officers, directors or managers. The Company shall not make or encourage any other
individual to make any public or private comments, orally or in written form (including, without limitation by e-mail or other electronic transmission), about Consultant, or take any action, directly or indirectly, that

  
 4 

 
would “disparage” Consultant. “Disparaging” statements are those which impugn the character, capabilities, reputation or integrity of the aforesaid individuals or entity or
which accuse the aforesaid individuals or entity of acting in violation of any law or governmental regulation or of condoning any such action, or otherwise acting in an unprofessional, dishonest, disreputable, improper, incompetent or negligent
manner, but shall not include truthful statements required by due legal process. 
 7. Representations of Consultant. Consultant
hereby represents and warrants as follows: 
 (a) Neither the execution or delivery of this Agreement nor the performance by the Consultant
of his duties and other obligations hereunder violate or will violate statute or law or conflict with ,or constitute a default or breach of any covenant or obligation, including without limitation any non-competition restrictions, under (whether
immediately, upon the giving of notice or lapse of time or both) any prior employment agreement, contract, or other instrument to which the Consultant is a party or by which he is bound. 

(b) The Consultant has the full right, power and legal capacity to enter and deliver this Agreement and to perform his duties and other
obligations hereunder. This Agreement constitutes the legal, valid and binding obligation of the Consultant enforceable against him in accordance with its terms. No approvals or consents of any persons or entities are required for the Consultant to
execute and deliver this Agreement or perform his duties and other obligations hereunder. 
 8. Termination. During the Term of this
Agreement, either party may terminate this Agreement upon 30 days prior written notice to the other. Upon any such termination: 
 (a)
Consultant shall be paid all compensation due through the date of termination and all accrued but unpaid expenses shall be paid upon the effective date of the termination; and 

(b) The vesting applicable to all unvested Options shall cease immediately and the Consultant shall have a period of 90 days to exercise any
and all vested Options, after which time all Options shall expire; provided, however, that no such Options shall be exercisable after June 30, 2014. 

9. Survival. Sections 5 and 6 shall survive any expiration or termination of this Agreement. 

10. Consultant not an Employee. Aerie and the Consultant hereby acknowledge and agree that Consultant shall perform the services
hereunder as an independent contractor and not as an employee of Aerie. 
 11. Miscellaneous. 

(a) Severability of Provisions. If any provision of this Agreement shall be declared by a court of competent jurisdiction to be
invalid, illegal or incapable of being 

  
 5 

 
enforced in whole or in part, the remaining conditions and provisions or portions thereof shall nevertheless remain in full force and effect and enforceable to the extent they are valid, legal
and enforceable, and no provision shall be deemed dependent upon any other covenant or provision unless so expressed herein. 
 (b)
Entire Agreement; Modification. This Agreement is the entire agreement of the parties relating to the subject matter hereof and the parties hereto have made no agreements, representations or warranties relating to the subject matter of this
Agreement which are not set forth herein or therein. No amendment or modification of this Agreement shall be valid unless made in writing and signed by each of the parties hereto. 

(c) Binding Effect. The rights, benefits, duties and obligations under this Agreement shall inure to, and be binding upon, Aerie, its
successors and assigns, and upon Consultant and his legal representatives. This Agreement constitutes a personal service agreement, and the performance of Consultant’s obligations hereunder may not be transferred or assigned by Consultant and
any such purported transfer or assignment shall null and void ab initio. 
 (d) Third Party Beneficiaries. This Agreement is for the
benefit of the parties hereto and their permitted successors and assigns, and is not intended to confer upon any other person or entity, any rights or remedies hereunder. 

(e) Non-Waiver. The failure of either party to insist upon the strict performance of any of the terms, conditions and provisions of
this Agreement shall not be construed as a waiver or relinquishment of future compliance therewith, and said terms, conditions and provisions shall remain in full force and effect. No waiver of any term or condition of this Agreement on the part of
either party shall be effective for any purpose whatsoever unless such waiver is in writing and signed by such party. 
 (f) Remedies For
Breach. Consultant agrees that any breach of Section 5, 6 or 7 of this Agreement by Consultant could cause irreparable damage to Aerie and to the Affiliates, and that monetary damages alone would not be adequate and, in the event of such
breach or threat of breach, Aerie shall have, in addition to any and all remedies at law and without the posting of a bond or other security, the right to an injunction, specific performance or other equitable relief necessary to prevent or redress
the violation of Aerie’s obligations under such Sections. In the event that an actual proceeding is brought in equity to enforce such Sections, Consultant shall not urge as a defense that there is an adequate remedy at law nor shall Aerie be
prevented from seeking any other remedies which may be available to it. 
 (g) Governing Law. This Agreement shall be governed by,
and construed and interpreted in accordance with, the laws of the State of New Jersey without regard to such State’s principles of conflict of laws. Any dispute arising out of, or relating to, this Agreement shall be exclusively decided by
binding arbitration conducted in New Jersey in accordance with the rules of the American Arbitration Association (the “AAA”) then in effect before a single arbitrator appointed in accordance with such rules. The arbitrator shall have
authority to grant any form of appropriate relief, whether legal or equitable in nature, including specific performance. Each of the parties agrees that service of process in such 

  
 6 

 
arbitration proceedings shall be satisfactorily made upon it if sent by registered mail addressed to it at the address referred to in clause below. Judgment upon any award rendered therein may be
entered and enforcement obtained thereon in any court having jurisdiction. 
 (h) Headings. The headings of the Sections are inserted
for convenience of reference only and shall not affect any interpretation of this Agreement. 
 (i) Counterparts and Execution. This
Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Facsimile, Portable Document Format (PDF) or photocopied signatures of the
Parties will have the same legal validity as original signatures. 
 [Remainder of page intentionally left blank] 

  
 7 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement by proper person
thereunto duly authorized. 
  

									
	AERIE PHARMACEUTICALS, INC.	 		 	THOMAS J. VAN HAARLEM, M.D.
					
	By:	 	 /s/ Richard J. Rubino
	 		 	By:	 	 /s/ Thomas J. van Haarlem

	Name:	 	Richard J. Rubino	 		 	Name:	 	Thomas J. van Haarlem
	Title:	 	CFO	 		 	Date:	 	07/25/13
	Date:	 	07/25/13	 		 		 	

  
 8EX-10.13

 Exhibit 10.13 

AERIE PHARMACEUTICALS, INC. 

135 US Highway 206, Suite 15 

Bedminster, NJ 07921 

September 24, 2012 
 Richard J. Rubino 

3 Apache Drive 
 Oakland, NJ 07436 

Tel: 201-247-9191 
 E-Mail: rich957@optonline.net 

 

	 	Re:	Your Employment with Aerie Pharmaceuticals, Inc. 

 Dear Richard, 

We are pleased to offer you, on the terms set forth in this letter (the “Agreement”), a position of employment as Chief
Financial Officer (“CFO”) of Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Your employment with the Company will start on October 15, 2012 (the “Start Date”). 

 

	 	1.	Reporting, Duties and Responsibilities, Employee Confidentiality, Inventions and Noncompetition; Indemnification. 

  

	 	a.	Reporting; Duties and Responsibilities. During the term hereof, from and after the Start Date until this Agreement is terminated as provided herein, you will serve as Chief Financial Officer, reporting to the
Chief Executive Officer of the Company (the “CEO”). Your specific duties and responsibilities as CFO will be determined by the CEO, but will primarily consist of leading the Company’s financial operations, strategy and
planning, managing financial audits in addition to contributing to any business transactions, fundraising and networking within the financial and investor community. This offer is for a full-time position at the Company’s New Jersey office,
except as travel to other locations may be necessary to fulfill your responsibilities. You may spend time for charitable, civic and academic responsibilities, and such other activities as the Board of Directors of the Company (the
“Board”) approves from time to time, as will not adversely impact your ability to perform your obligations hereunder, with such impact being determined, as necessary, by the CEO in good faith after reasonable consultation with you
with respect thereto. 

  

	 	b.	Employee Confidentiality, Inventions and Noncompetition Agreement. As a condition of your employment hereunder, you shall on or prior to the Start Date execute the Company’s standard form of Confidentiality,
Inventions and Noncompetition Agreement (the “Confidentiality, Inventions and Noncompetition Agreement”). 

	 	c.	Indemnification. You will be subject to such indemnification as is provided under the Company’s Bylaws. 

  

	 	2.	Salary; Bonuses; Benefits; Reimbursement; Relocation; Stock Options. 

  

	 	a.	Salary. Your initial annual base salary rate (less applicable deductions), commencing on the Start Date, will be at a rate of $12,500 per semi-monthly pay period, prorated for partial periods, which is an
annualized salary rate of $300,000, subject to increase by the CEO and the Board, payable in accordance with the Company’s customary payroll practice as in effect from time to time. Your salary as in effect at the time during the term hereof
may not be decreased by the Board except as a proportional reduction, as to the salaries of all other officers of the Company at the level of Vice President and above as part of an overall reduction in salaries decided by the Board in good faith as
being in the best interests of the Company and its stockholders, and will only be so reduced during such time as all such other executive officer salaries remain so reduced. 

 

	 	b.	Bonuses. 

  

	 	i.	Annual Performance Bonus. In addition to your salary, during the Term of your employment with the Company, you will be eligible to earn an annual performance-based bonus (the “Annual Bonus”) as
follows: 

  

	 	(A)	Amount. Such annual bonus as to your performance for 2012 or a subsequent year will equal up to twenty percent (20%) of your annual salary for the relevant calendar year, or, as determined by the CEO and the
Board of the Company, to which such Annual Bonus relates. Your 2012 Annual Bonus will be prorated to the Start Date. The exact amount of any Annual Bonus for each calendar year will be determined in good faith by the Board in its complete and sole
discretion on the same date as such determination is made for all other executive officers of the Company, but in no event later than April 1 of the calendar year following the performance period based on your achievement of objectives for the
relevant performance measurement period. If a bonus is awarded, it will be paid between January 1 and April 15 of the calendar year following the one to which it relates. 

  
 2 

	 	(B)	Objectives. No later than sixty (60) days after the Start Date, the CEO, or the Compensation Committee of the Board, and you will mutually determine in good faith your performance objectives for calendar
year 2012, which agreed objectives will be set forth in writing by the CEO to you and which thereafter cannot be changed for such calendar year without written notice to you. If you and the CEO, or the Compensation Committee as applicable, do not
agree upon such objectives for the relevant year within such 60 day period, then the objectives will be determined by the CEO, in his sole discretion, within 30 days after such 60 day period has expired and will be communicated to you in writing
after being so determined and will be deemed to have been accepted by you. Thereafter, the procedures set forth above will be followed for any subsequent years in which you are employed by the Company. 

 

	 	c.	Benefits. From and after the Start Date, during your employment hereunder: 

  

	 	i.	Benefits Generally. You will receive the Company’s standard employee benefits package (including health and disability insurance paid by the Company, participation in the Company’s 401(k) plan subject
to the terms and conditions thereof) as such packages and policies are in effect from time to time, and as such benefits package may be adjusted by the Board in good faith during the term hereof, as applicable to all employees, which benefits
package can be increased, but cannot be decreased unless such decrease is effected in connection with, and is proportional to, an overall reduction in the relevant benefits to all executive officers decided by the Board in good faith as being in the
best interests of the Company and its stockholders, and will only be so reduced during such time as all such other relevant executive officer benefits remain so reduced. In addition, you will be entitled to paid time off in accordance with Company
policy. 

  

	 	ii.	Life Insurance. Within ninety (90) days of the Start Date, the Company will provide you, at the Company’s expense, as part of such benefits package, with a life insurance benefit plan with terms and
coverage appropriate for your position, but in no event less than one year’s Base Salary. 

  

	 	d.	 Reimbursement. You will be entitled to reimbursement from the Company for all commercially reasonable and documented out-of-pocket expenses
incurred by you in connection with the Company’s business, including without limitation, your reasonable domestic economy airfare, food, lodging, automobile rental and incidental expenses in performing your duties hereunder, provided, as to a
given expense, that you have 

  
 3 

	 	
submitted commercially customary support documentation within thirty (30) days of incurring such expense. You will obtain the approval of the CEO in writing prior to incurring any expenses
other than ordinary course expenses as described generally in the preceding sentence of this Section 2(d). 

  

	 	e.	Stock options. 

  

	 	i.	Initial Option. You will be granted, subject to Board approval at the first Board meeting held after the Start Date, an incentive stock option (your “Initial Option”) under the Company’s
current stock option plan (the “Plan”), to purchase up to One Million Seven Hundred Twenty Five (1,725,000) shares of Common Stock of the Company. The exercise price per share of your Initial Option will be equal to the fair
market value per share of the Company’s Common Stock as of the date that such Initial Option is granted by the Board. Such Initial Option will become exercisable over the forty-eight (48) month period commencing with the Start Date (the
“Vesting Start Date”), as to 25% of the total number of shares under such Initial Option on the first annual anniversary of the Vesting Start Date, rounded downward to the nearest whole share to avoid fractional shares, and will
become exercisable as to an additional 2.084% of the total number of shares under such Initial Option at each of the succeeding 36 monthly anniversaries after such one year anniversary, rounded downward to the nearest whole share for the
first 35 of such monthly anniversaries to avoid fractional shares, and as to the remaining number of shares under such Initial Option at the 48th monthly anniversary of the Vesting Start Date, provided as to such one-year anniversary and as to each
such relevant monthly anniversary thereafter you then are employed by or are rendering services as a consultant to the Company. 

  

	 	ii.	Other Options or Awards. During the term hereof, you will also be eligible to be granted such other stock options and/or stock awards, under or outside of the Plan and under any successor equity incentive plans
of the Company, as the Company deems to be appropriate. 

  

	 	f.	Taxes. You shall be responsible for any taxes payable with regard to any compensation of benefits provided for in this Agreement. 

 

	 	3.	Representations and Warranties. 

  

	 	a.	 You represent and warrant to the Company that your performance of this Agreement and employment with the Company does not and will not breach any
noncompetition agreement or any agreement to keep in 

  
 4 

	 	
confidence proprietary information acquired by you in confidence or in trust prior to your employment with the Company. You also represent and warrant to the Company that you have not entered
into, and during the Term, agree not to enter into, any agreement that conflicts or violates this Agreement. 

  

	 	b.	You represent and warrant to the Company that you have not brought and shall not bring to the Company, or use in the performance of your responsibilities for the Company, any materials or documents of a former employer
which are not generally available to the public or which did not belong to you prior to your employment with the Company, unless you have obtained written authorization from the former employer or other owner for their possession and use and
provided the Company with a copy thereof. 

  

	 	4.	Certain Definitions; “At Will” Basis of Your Employment; Term; Survival of Certain Obligations; Post-Termination Matters. 

 

	 	a.	“At Will” Basis of Your Employment; Term. Your employment with Company is on an “at will” basis, and either you or the Company may terminate your employment with the Company at any time, for
any reason, or for no reason, with written notice to you of any voluntary termination by you, provided that, if you desire to terminate this Agreement voluntarily, you will give the Company at least thirty (30) days prior written notice of the
intended effective date of such voluntary termination, which notice period may be waived or shortened by the Company upon your giving to the Company such written notice. Unless terminated earlier as provided herein, including “at will”
termination, or unless extended in writing by you and the Company, the term of this Agreement is for three (3) years from and after the Start Date, ending at 5:00 p.m. local time at the then current location of the principal offices of the
Company, on the third (3rd) annual anniversary of the Start Date. 

  

	 	b.	Post-Termination Matters. 

  

	 	i.	Automatic Resignation From Office. By your signature on this Agreement, unless the Company agrees otherwise in writing with you, this Agreement will serve automatically, without the need for any further
signatures, as your resignation, effective as of the date of your termination of employment hereunder, for whatever reason, from any and all offices you may hold with the Company or any subsidiary or other affiliate of the Company at the date of
such termination. 

  

	 	ii.	 Return of Materials. Upon any termination hereof, you will promptly return to the Company all copies and originals of documents and other
tangible impressions, in any medium, 

  
 5 

	 	
containing confidential or proprietary information of the Company. After such termination you will not disclose to any party, other than to your attorneys, or except to the extent required by
law, any such information which is not at the time of disclosure otherwise public information through no breach by you of your obligations of confidentiality under this Section 4(b)(ii), provided that if there is in effect at the date of such
determination a written nondisclosure agreement between you and the Company, the terms and conditions of such nondisclosure agreement will govern over the provisions in this sentence. 

 

	 	iii.	Accrued Salary and Bonus. After such termination, the Company will only be obliged to pay, and will pay when due, to you only such amounts of salary and bonus (if any) accrued under any bonus plan through, and
payable at, the date of such termination. 

  

	 	iv.	Expenses. The Company will pay reasonably promptly all expenses permitted to be reimbursed hereunder for which appropriate documentation has been submitted by you. 

 

	 	v.	Non-solicitation. In order to avoid disruption of the Company’s business, for a period of one (1) year after termination of your employment hereunder for any reason other than your death, you will not,
directly or indirectly, (A) solicit for any competitor to the Company, or for any other purpose competitive with the Company, any customer of the Company known to you during the period of your employment with the Company to have been a customer
of the Company, (B) directly or indirectly encourage or induce any third party licensor, licensee, distributor or research, development or commercialization collaborator of the Company to terminate or reduce its business activities with the
Company, or (C) solicit for employment any person employed by the Company. 

  

	 	5.	Dispute Resolution. 

  

	 	a.	 Arbitrable Claims; Intended Third-Party Beneficiaries. To the fullest extent permitted by law, except for disputes relating to intellectual
property of the Company, for which the parties reserve the right to resolution by litigation and which will not be Arbitrable Claims, all disputes between you (and your attorneys, successors, and assigns) and the Company (and its affiliates,
shareholders, Directors, officers, employees, agents, successors, attorneys, and assigns) of any kind whatsoever, including, without limitation, all disputes relating in any manner to the employment by the Company of you, or the termination of your
employment by the Company, and all disputes arising under this Agreement, including without limitation any disputes as to matters arising after the Start Date, whether or not the Start Date ever occurs (collective,

  
 6 

	 	
and individually, “Arbitrable Claims”) will be resolved by arbitration as provided herein. Arbitrable Claims will include, but are not limited to, contract (express or implied)
and tort claims of all kinds, as well as all claims based on any federal, state, or local law, statute, or regulation, excepting only claims under applicable workers compensation law and unemployment insurance claims. By way of example and not in
limitation of the foregoing, Arbitrable Claims will include (to the fullest extent permitted by law) any claims arising under Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the New Jersey Law Against Discrimination
as well as any claims asserting wrongful termination, harassment, breach of contract, breach of the covenant of good faith and fair dealing, negligent or intentional infliction of emotional distress, negligent or intentional misrepresentation,
negligent or intentional interference with contract or prospective economic advantage, defamation, invasion of privacy, and claims related to disability. All persons and entities specified in the first sentence of this Section 5(a), other than
the Company and you, will be considered third-party beneficiaries of the rights and obligations created by this Section 5. 

  

	 	b.	Procedure; Location Of Arbitration. Arbitration of Arbitrable Claims will be in accordance with the National Rules for the Resolution of Employment Disputes of the American Arbitration Association, as amended
(“AAA Employment Rules”), as augmented in this Agreement. Arbitration will be initiated as provided by the AAA Employment Rules, although the written notice to the other party initiating arbitration will also include a statement of
the claim(s) asserted and the facts upon which the claim(s) are based. Arbitration will be final and binding upon the parties and will be the exclusive remedy for all Arbitrable Claims. Either party may bring an action in court to compel arbitration
under this Agreement and to enforce an arbitration award. Otherwise, neither party will initiate or prosecute any lawsuit or administrative action in any way related to any Arbitrable Claim. All arbitration hearings under this Agreement will be
conducted in the city in which the principal offices of the Company are located at the time of initiation of such arbitration. The Federal Arbitration Act will govern the interpretation and enforcement of this Section 5. THE PARTIES HEREBY
WAIVE ANY RIGHTS THEY MAY HAVE TO TRIAL BY JURY IN REGARD TO ARBITRABLE CLAIMS, INCLUDING WITHOUT LIMITATION ANY RIGHT TO TRIAL BY JURY AS TO THE MAKING, EXISTENCE, VALIDITY, OR ENFORCEABILITY OF THE AGREEMENT TO ARBITRATE. 

 

	 	c.	 Arbitrator Selection and Authority. Arbitration shall be initiated and all Claims shall be decided by a single, neutral arbitrator in
accordance with the AAA Employment Rules. The arbitrator will have authority to award equitable relief, damages, costs, and fees to the greatest extent permitted by law, including, but not limited to, any remedy or relief that a court would have.
The arbitrator will have exclusive authority to resolve all 

  
 7 

	 	
Arbitrable Claims, including, but not limited to, whether any particular claim is arbitrable and whether all or any part of this Agreement is void or unenforceable. 

 

	 	d.	Litigation. For matters arising hereunder for which arbitration is not legally available, and for disputes between you and the Company as to intellectual property rights, you and the Company hereby consent to
venue in, and to the in personam jurisdiction of, the federal and State courts located in the State of New Jersey. 

  

	 	e.	Confidentiality. All proceedings and all documents prepared in connection with any Arbitrable Claim will be confidential and, unless otherwise required by law, the subject matter thereof will not be disclosed to
any person other than the parties to the proceedings, their counsel, witnesses and experts, the arbitration panel, and, if involved, the court and court staff. All documents filed with the arbitration panel or with a court will be filed under seal
to the extent permitted by the applicable rules. The parties will stipulate to all arbitration and court orders necessary to effectuate fully the provisions of this subsection concerning confidentiality. 

 

	 	f.	Expenses of Arbitration. Each party will pay its own expenses for participation in such arbitration, including the fees and expenses of such party’s legal counsel and other advisors, provided that the
Company will pay all fees and expenses of the arbitrators and any fees or charges imposed by the arbitral body for such arbitration, provided that the arbitral body shall have authority to require you to pay fees or charges if you initiate the
arbitration and it determines that your claims are frivolous or without merit. 

  

	 	g.	Continuing Obligations. Your rights and obligations and those of the Company set forth in this Section 5 will survive the termination of your employment with the Company. 

 

	 	6.	 Notices. All notices, demands or requests with respect to this Agreement will be effective only if in writing and delivered by hand, including
by FedEx or other courier, or by facsimile with confirmed answerback, or by electronic mail (email) with electronic evidence of delivery, to the address, or the facsimile number, or email, for the receiving party as set forth under our signatures
below. Notices under this Agreement may not be delivered by mail. Notices will be deemed to have been given hereunder upon personal delivery, if delivered by hand, or the date sent by facsimile or email. You and the Company may change
the relevant address for notice under this Agreement by giving notice thereof to the other party hereto in conformity with this Section 6. Whenever days are to be counted under this Agreement, the first day of the period which requires such
notice to be given will not be counted, and the last day for the relevant period will be counted (i.e., 

  
 8 

	 	
to count a 30-day period following the Start Date, the first day after the Start Date will be the first day for counting such 30 days). 

 

	 	7.	General. This Agreement will be governed by the laws of the State of New Jersey, without regard to its body of law controlling conflict of laws. This Agreement may be executed in two (2) counterparts, each
of which will be an original and both of which together will constitute one and the same instrument. Upon your signature below, this will become our binding Agreement with respect to the subject matter of this letter, superseding in their entirety
all other or prior Agreements by you with the Company as to the specific subject matter of this Agreement, will be binding upon and inure to the benefit of our respective successors and assigns (provided that you cannot assign this Agreement or any
of your rights and obligations under this Agreement without the prior written consent of the Company), and your heirs, administrators and executors, and may only be amended in a writing signed by you and the Company. 

We look forward to working together with you for the success of the Company. 

 

			
	 Sincerely,
  

	 AERIE PHARMACEUTICALS, INC.
  

	By:	 	 /s/ Thomas J. van Haarlem, M.D.

	Name:	 	Thomas J. van Haarlem, M.D.
	Title:	 	President & Chief Executive Officer
	Address:
	1335 US Highway 206, Suite 15
	Bedminster, NJ 07921
	Phone: 908-470-4320
	Facsimile: 908-470-4329
	Email: tvanhaarlem@aeriepharma.com

  

			
	 ACCEPTED AND AGREED:
  

	By:	 	 /s/ Richard J. Rubino

		
	Name:	 	Richard J. Rubino
	Date signed: 10-3-12
	Address: 3 Apache Drive, Oakland, NJ 07436
	Phone: Tel: 201-247-9191
	E-Mail: rich957@optonline.net

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]